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Abstract
Background: Achieving target levels of laboratory parameters of bone and mineral metabolism in chronic kidney
disease (CKD) patients is important but also difficult in those living with end-stage kidney disease. This study aimed
to determine if there are age-related differences in chronic kidney disease-mineral and bone disorder (CKD-MBD)
characteristics, including treatment practice in Hungarian dialysis patients.
Methods: Data were collected retrospectively from a large cohort of dialysis patients in Hungary. Patients on
hemodialysis and peritoneal dialysis were also included. The enrolled patients were allocated into two groups
based on their age (<65 years and ≥65 years). Characteristics of the age groups and differences in disease-related
(epidemiology, laboratory, and treatment practice) parameters between the groups were analyzed.
Results: A total of 5008 patients were included in the analysis and the mean age was 63.4±14.2 years. A total of
47.2% of patients were women, 32.8% had diabetes, and 11.4% were on peritoneal dialysis. Diabetes (37.9% vs
27.3%), bone disease (42.9% vs 34.1%), and soft tissue calcification (56.3% vs 44.7%) were more prevalent in the
older group than the younger group (p<0.001 for all). We found an inverse relationship between age and
parathyroid hormone (PTH) levels (p<0.001). Serum PTH levels were lower in patients with diabetes compared with
those without diabetes below 80 years (p<0.001). Diabetes and age were independently associated with serum PTH
levels (interaction: diabetes × age groups, p=0.138). Older patients were more likely than younger patients to
achieve laboratory target ranges for each parameter (Ca: 66.9% vs 62.1%, p<0.001; PO4: 52.6% vs 49.2%, p<0.05; and
PTH: 50.6% vs 46.6%, p<0.01), and for combined parameters (19.8% vs 15.8%, p<0.001). Older patients were less
likely to receive related medication than younger patients (66.9% vs 79.7%, p<0.001).
Conclusions: The achievement of laboratory target ranges for bone and mineral metabolism and clinical practice in
CKD depends on the age of the patients. A greater proportion of older patients met target criteria and received less
medication compared with younger patients.
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Background
The prevalence of chronic kidney disease (CKD), and
consequently, dialysis therapy and appearance of co-
morbidities, is continuously increasing in the developed
world because of the high prevalence of well known risk
factors and aging of the population. One of the most fre-
quent complications of CKD is chronic kidney disease-
mineral and bone disorder (CKD-MBD) [1,2]. In CKD-
MBD, characteristic laboratory parameters (parathyroid
hormone [PTH], calcium [Ca], and phosphate [PO4]) are
strongly associated with mortality and morbidity. In
clinical practice, there is a considerable amount of patients
with laboratory parameters concurrently outside the
normal target ranges, which further aggravates the risk of
morbidity and mortality [3-6]. The appearance of cardio-
vascular diseases may also be caused by vascular calcifica-
tion, which is strongly linked with disruptions in Ca and
PO4 metabolism [7]. The lack of related evidence-based
data also contributes to continuous changes in clinical
guidelines [8-14].
One of the consequences of an aging population is that
the vast majority of dialyzed CKD patients are older than 65
years old. As a result, renal replacement therapy has
become part of geriatric medicine [15]. In elderly CKD
patients, there are some special considerations, such as cog-
nitive and functional impairment, falls, and bone fractures.
Consequently, these conditions also require different treat-
ment practice, and elderly CKD patients have different
characteristics compared with younger age groups.
To determine CKD-MBD disease characteristics and
treatment practice in Hungary and compare them with
international data, we performed a survey among adult
Hungarian dialysis patients to audit therapeutical prac-
tice. Our hypothesis is that there are different disease
characteristics and treatment practices between patient
groups according to age. We expect local health care-
givers to treat their patients more individually and in
general, to focus more on CKD-MBD issues, which has
been observed internationally. According to a recent
report, a focused 18-month campaign resulted in an
increased proportion of patients who achieved serum Ca
and PO4 targets by 24% and 8%, respectively [16]. In
addition, the results of this survey should be helpful for
improving patient education, the importance of which is
also endorsed by international experience [17,18].
The first aim of this survey was to describe characteristics
of patients regarding their CKD-MBD status in Hungary.
Furthermore, we analyzed the characteristics of patients in
different age groups. The second aim was to analyze the dif-
ferences between laboratory test results of bone metabol-
ism markers (PTH, Ca, and PO4) and prescribed therapies
in different age groups. Finally, we compared our results
with international experience and data, setting the neces-
sary direction for development in Hungary.
Methods
This was a multicenter observational survey. We enrolled
5335 chronic dialysis patients (for at least 3 months on
renal replacement therapy) from all dialysis units in
Hungary. (participating investigators and units are listed
in the Acknowledgements.) Patients on hemodialysis
(HD) and peritoneal dialysis (PD) were included. Patients
with one or more basic values missing were excluded from
the survey. The final dataset included 5008 patients. To
identify age-dependent conclusions, we divided the study
population into groups based on their ages (group I: <65
years; group II: ≥65 years).
The survey was performed between December 2010
and March 2011. We collected cross-sectional clinical,
laboratory, and treatment data from the second quarter
of 2010. Patient identity codes, sex, birth year, height
and weight, cause of CKD, and the presence of com-
plications, such as diabetes, bone disease, soft tissue
calcification, and parathyroidectomy, were included in
the dataset. Dialysis physicians completed an electronic
survey for each patient regarding the presence of bone
abnormalities. Bone abnormalities were defined as any
radiologically documented bone fracture or other bone
abnormality and vascular calcification or tissue calcinosis
detected by any imaging technique. Laboratory parame-
ters measured were serum intact parathyroid hormone
(se-iPTH), serum PO4, Ca, and albumin levels. Samples
were analyzed in different laboratories based on the lo-
cation and dialysis provider's preference. In case of PTH,
the vast majority of blood samples were analyzed by
either the Elecsys (Roche Diagnostics, Meylan, France)
intact PTH assay or the Architect (Abbott Diagnostics,
Abbott Park, Il, USA) intact PTH assay. We also
collected data on prescribed medications, including
phosphate binders, vitamin D analogs, and calcimimetic
agents. All laboratory- and treatment-related data were
captured from the databases of dialysis providers.
Results are presented as mean ± standard deviation
(SD) or in absolute and relative frequencies (%) for con-
tinuous and categorical variables, as appropriate. The
levels of se-iPTH followed log-normal distribution, and
therefore, we chose to use the geometric mean and 95%
confidence interval (CI), as well as median and 1–3
quartiles. Differences between patient groups were com-
pared using the Student's t-test or ANOVA. Tukey’s test
was used for post-hoc analysis. The Kruskal–Wallis and
Mann–Whitney U tests were used for continuous vari-
ables and the z-test for categorical variables. To demon-
strate the association of se-iPTH with age, diabetes, and
other parameters of dialysis patients, we analyzed the
data by two-way ANOVA, multivariate linear regression,
and multivariate logistic regression models. Statistical
analysis was performed by the Statistica software pro-
gram (version 10.0, Tulsa, Oklahoma, USA).
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All patients were informed about details of the survey
and gave written consent for the collection and scientific
analysis of their individual data. This study was approved
by the nationwide ethical authority (Medical Research
Council Scientific and Ethical Committee [ETT-TUKEB];
approval number: 384/PI/2010; 5372-0/2010-1018EKU).
Results
The mean age of the 5008 dialyzed CKD patients was
63.4±14.2 years and 47.2% were women. The patients
were distributed almost equally between the two age
groups (group I: n=2413 and group II: n=2595) (Table 1).
The proportion of female patients was higher in the
older group than in the younger group (52.8% vs 41.2%,
p<0.001). Interestingly, mean body mass index was com-
parable in both age groups and sexes. The leading causes
of ESRD were hypertensive nephrosclerosis (22.9%)
and diabetic nephropathy (22.1%). Hypertensive nephro-
sclerosis, diabetic nephropathy, and tubulointerstitial
disease were more prevalent in the older group than in
the younger group (p<0.001), whereas the proportions of
glomerulonephritis and polycystic disease were higher in
the younger group than in the older group (p<0.001).
Diabetes as a co-morbid condition was also more fre-
quent in the older group than in the younger group
(37.9% in group II and 27.3% in group I, p<0.001). A
total of 38.6% of all patients had previously defined bone
disease(s) and the proportion of soft tissue calcification
Table 1 Demographic and laboratory data of the two age groups
Total (n=5008) Age-groups (years) Comparison of groups
I. <65 (n=2413) II. ≥65 (n=2595)
Age (year) 63.4 ± 14.2 51.5 ± 10.1 74.5±6.3 -
Gender (%) Male 2644 (52.8%) 1418 (58.8%) 1226 (47.2%) p<0.001
Female 2364 (47.2%) 995 (41.2%) 1369 (52.8%)
BMI (kg/m2) Male 26.8 ± 5,2 27.0 ± 5.7 26.7 ± 4.6 NS
Female 26.4 ± 6,1 26.4 ± 7.0 26.4 ± 5.4 NS
Dialysis modality (%) PD 569 (11.4% ) 341 (14.1%) 228 (8.9%) p<0.001
HD 4439 (88.6%) 2072 (85.9%) 2367 (91.2%)
intact PTH (pg/ml) (median, quartiles) 178.0 75.8–361.5 206.0 82.2–451.0 157.0 70.0–30.2 p<0.001
intact PTH (pg/ml) (geometric mean, 95% CI of mean) 158.7 153.5–169.1 184.9 175.7–194.6 136.7 131.6–143.8 p<0.001
Calcium (mmol/l) 2.25 ± 0.19 2.24 ± 0.21 2.26 ± 0.17 p<0.001
Phosphate (mmol/l) 1.50 ± 0.49 1.63 ± 0.50 1.39 ± 0.43 p<0.001
CaxP (mmol2/l2) 3.38 ± 1.10 3.63 ± 1.15 3.14 ± 0.99 p<0.001
Albumin (g/l) 39.4 ± 4.2 39.9 ± 4,3 38.9 ± 4.1 p<0.001
Diabetes mellitus (%) 1641 (32.8%) 658 (27.3%) 983 (37.9%) p<0.001
Bone disease (%) 1935 (38.6%) 822 (34.1%) 1113 (42.9%) p<0.001
Soft tissue calcification (%) 2540 (50.7%) 1078 (44.7%) 1462 (56.3%) p<0.001
Parathyroidectomy (%) 104 (2.1%) 84 (3.5%) 20 (0.8%) p<0.001
Cause of ESRD Glomerulonephritis 813 (16.2%) 524 (21.7%) 289 (11.1%) p<0.001
Tubulointerstitial 695 (13.9%) 293 (12.1%) 402 (15.5%) p<0.001
Diabetes mellitus 1105 (22.1%) 455 (18.9%) 650 (25.1%) p<0.001
Hypertension 1146 (22.9%) 464 (19.2%) 682 (26.3%) p<0.001
Polycystic 379 (7.6%) 238 (9.9%) 141 (5.4%) p<0.001
Unknown 189 (3.8%) 99 (4.1%) 90 (3.5%) NS
other 681 (13.6%) 340 (14.1%) 341 (13.1%) NS
Prescribed therapy (%) Calcimimetic 259 (5.2%) 196 (8.1%) 63 (2.4%) p<0.001
Ca based PO4-binder 2011 (40.2%) 1033 (42.8%) 978 (37.7%) p<0.001
Non-Ca based PO4-binder 947 (18.9%) 626 (25.9%) 321 (12.4%) p<0.001
Native vitamin D 166 (3.3%) 89 (3.7%) 77 (3.0%) NS
Active vitamin D 2020 (40.4%) 1037 (43%) 983 (37.9%) p<0.001
None 1349 (26.9%) 489 (20.3%) 860 (33.1%) p<0.001
NS non-significant.
Kiss et al. BMC Nephrology 2013, 14:155 Page 3 of 8
http://www.biomedcentral.com/1471-2369/14/155
was as high as 50.7%. Bone disease and soft tissue calcifi-
cation were significantly more frequent findings in the
older group than in the younger group (bone disease:
42.9% vs 34.1%, p<0.001; calcification: 56.3% vs 44.7%,
p<0.001).
A total of 569 (11.4%) patients were on PD and 4439
(88.6%) were on HD. The proportion of PD patients was
lower in the older group than in the younger group
(8.9% vs 14.1%, p<0.001). There were no differences in
epidemiological or laboratory parameters between these
patient groups. The prevalence of diabetes was similar
(32.7%) between PD and HD patients. However, bone
disease (39.9% vs 29.2%) and soft tissue calcification
(52.7% vs 35.5%) were more frequent in HD than in PD
patients (p<0.001). Separate analyses were conducted for
the two patient groups, which resulted in similar results
(data not shown). Therefore, we only reported results
for the whole patient population.
Laboratory test results are summarized in Table 1.
Serum iPTH and PO4 levels were significantly lower
(p<0,001) in the older group than in the younger group.
Serum calcium and albumin levels were also significantly
different between age groups. However, we do not be-
lieve that these differences are clinically relevant.
To further determine the associations among age, dia-
betes, and PTH levels, we divided the study population into
five age groups (<50; 50–59; 60–69; 70–79; ≥80). Using
these categories, we observed decreasing PTH levels with
increasing age in both diabetes and non-diabetes subgroups
(two-way ANOVA, p<0.001 for all comparisons; p=0.138
for the interaction diabetes × age) (Figure 1). Apart from
the highest age group (≥80 years), se-iPTH levels were
always significantly higher in the non-diabetes subgroup. In
multivariate linear regression with PTH as the continuous
dependent variable, age (b=−3.61, p<0.001), diabetes
(b=−79.76, p<0.001), Ca (b=−145.13, p<0.001), and PO4
(b=165.76, p<0.001) were independent predictors of PTH.
In logistic regression, age (10-year increments, odds ratio
[OR] 1.07 [1.02–1.11], p<0.01), diabetes (OR 1.33 [1.17–
1.51], p<0.001), serum PO4 levels (0.1 mmol/l increments,
OR 0.92 [0.91–0.94], p<0.001) and serum Ca levels (0.1
mmol/l increments, OR 1.23 [1.19–1.27], p<0.001) were in-
dependent predictors of PTH levels <120 pg/ml (Table 2).
In a similar model, age ≥65 years increased the risk of PTH
<120 pg/ml by 33% (OR 1.33 [1.18-1.49], p<0.001).
The proportion of patients who achieved laboratory
targets in the age groups is shown in Table 3. Although
serum Ca levels were significantly higher in the older
group (Table 1), more patients in this group reached the
target range (p<0.001). Approximately half of the pa-
tients met the target criteria for PO4, and this was
slightly higher in the older group than in the younger
group (p<0.05). Similarly, a higher proportion of patients
in the older group than in the younger group had their
PTH levels in the reference range of 120–540 pg/ml
(50.6% vs 46.6%, p<0.01). We also found a higher propor-
tion of patients with PTH levels lower than 120 pg/ml in
the older group compared with the younger group (40.2%
vs 33.4%, p<0.001). If all three parameters were combined,
the simultaneous achievement of targets in the younger
group was 15.8%, which was significantly (p<0.001) lower
than that in the older group (19.8%). The percentage of
patients who achieved all three laboratory targets was only
17.9% (n=896). Serum Ca and iPTH levels in the patients
are shown in Table 4. A total of 32.9% of patients achieved
both laboratory targets.
The proportions of patients receiving different CKD-
MBD-related medications are shown in Table 1. There
was a considerable number of patients (n=1349; 26.9%)
who were not prescribed any of these drugs. Older pa-
tients were less likely than younger patients (p<0.001) to
receive any of the listed medications, with the exception
of native vitamin D (cholecalciferol), which was pre-
scribed to a minority of patients in both groups (3.7%
and 3.0%). The majority of patients received Ca-based
phosphate binders rather than non-Ca-based phosphate
binders (40.2% vs 18.9%). The prescription of non-
Ca-based phosphate binders was higher than Ca-based
phosphate binders only in the subgroup with PTH levels
>540 pg/ml and Ca levels >2.4 mmol/l. A total of 43.1% of
patients with PTH levels <120 pg/ml and Ca levels
>2.4 mmol/l were prescribed Ca-based phosphate binders.
Figure 1 Association between serum iPTH level, age, and
diabetes. Two-way ANOVA: DM p<0,001; age groups p<0,001;
interaction DM x age groups p=0,138.
Table 2 Predictors of iPTH<120 pg/ml using a multivariate
logistic regression model
Odds ratio 95% CI p
Age (10 years increments) 1.07 1.02 – 1.11 <0.01
Ca (0.1mmol/l increments) 1.23 1.19 – 1.27 <0.001
PO4 (0.1 mmol/l increments) 0.92 0.91 – 0.94 <0.001
Gender (male vs female) 1.09 0.97 – 1.23 NS
NS non-significant.
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Among patients receiving phosphate binders, older pa-
tients were more likely to receive Ca-based binders
(75.3%) compared with younger patients (62.3%). How-
ever, soft tissue calcification was more prevalent in the
older group than in the younger group. While approxi-
mately 10% of patients in the high PTH group did not
have therapy, only approximately 60% of those received
active vitamin D analogs, and only 24.1% of hypercalcemic
patients in this subgroup were treated with a calcimimetic
agent. A total of 31.6% of hypercalcemic patients with
PTH levels below the target range received active vitamin
D analogs and some patients also received a calcimimetic
agent in this PTH subgroup.
Treatment patterns are shown for the two age groups
in Table 5. We found a higher prevalence of older pa-
tients than younger patients meeting CKD-MBD target
values (19.8% vs 15.8%, p<0.001), despite a lesser need of
therapy in this patient group. Considering patients who
were within the target ranges for all parameters (Ca,
PO4, and PTH), 30.7% did not require treatment in the
older group, and this proportion was higher than that in
the younger group (18.8%, p<0.001). When comparing
patients who received treatment versus those who did
not receive treatment in the older group, the proportion
of patients meeting target criteria was not different for
PTH (53.3% vs 50.4%, p: NS) and PO4 (52.7% vs 52.4%,
p: NS). Patients who received treatment were slightly
less likely to fall in the target range for Ca (64.9% vs
69.0%, p<0.05).
Discussion
In this multicenter cross-sectional study among 5008
dialysis patients in Hungary, we found an inverse rela-
tionship between se-iPTH and age, and this was inde-
pendent from the association between diabetes and
iPTH. We also found that a higher proportion of older
patients achieved treatment targets, whereas a lower
proportion of these patients received therapy than in
younger patients. In addition, our study showed that
medication prescription practice did not follow current
therapeutic guidelines in a significant proportion of pa-
tients in 2010.
More than half of our study population was aged older
than 65 years. We showed that this significant propor-
tion of patients was better controlled according to the
CKD-MBD guidelines compared with younger patients,
despite the lesser need for medication. Serum PO4 levels
were lower in elderly patients than in younger patients,
despite a lower use of Ca and non-calcium-based PO4
binders. This finding could reflect lower PO4 intake in
elderly patients compared with younger patients. How-
ever, lower phosphorous could be a result of lower PTH
levels in older patients.
Serum iPTH levels were lower in patients older than
65 years of age than in those younger than 65 years. Eld-
erly patients were more likely to have PTH levels in the
target range, and the prevalence of PTH levels below the
target range was also higher in elderly patients. This
finding is unlikely to be a result of overtreatment of
secondary hyperparathyroidism because active vitamin D
analogs and calcimimetic were less prevalent in the older
group than in the younger group. Lower PTH levels in
elderly patients could reflect a higher inflammatory state
in these patients or the former prescription of aluminum-
based phosphate binders. These findings are consistent
with those in a previous study by Pelletier et al. [19] in a
large cohort of HD patients in France.
An inverse association between age and PTH has been
proposed in previous studies [20,21]. Iatrogenic factors
may contribute to hypoparathyroidism. Elderly patients
are more likely to be treated with Ca-based phosphate
binders compared with younger patients. A relatively
higher Ca burden may suppress PTH production. In
addition, elderly patients are more likely to receive
Table 3 Numbers and proportions of patients who achieved laboratory targets in different age groups
Laboratory parameters <65 years (n=2413; 48.2%) ≥65 years (n=2595; 51.8%) Comparisons of groups
Ca (2.1-2.4) 1499 (62.1%) 1736 (66.9%) p<0.001
PO4 (1.2-1.8) 1186 (49.2%) 1364 (52.6%) p<0.05
iPTH (120–540) 1124 (46.6%) 1312 (50.6%) p<0.01
Ca/PO4/PTH in the target range 382 (15.8%) 514 (19.8%) p<0.001
Table 4 Number and proportion of patients based on their serum iPTH and Ca levels
Se–Ca (mmol/l) Total
<2.1 2.1-2.4 >2.4
Se– iPTH (pg/ml) <120 208 (4.2%) 1172 (23.4%) 469 (9.4%) 1849 (36.9%)
120-540 494 (9.9%) 1647 (32.9%) 295 (5.9%) 2436 (48.6%)
>540 170 (3.4%) 416 (8.3%) 137 (2.7%) 723 (14.4%)
Total 872 (17.4%) 3235 (64.6%) 901 (18.0%) 5008 (100.0%)
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aluminum-based phosphate binders that also may aggra-
vate hypoparathyroidism. Lower serum albumin concen-
trations in the older group suggests malnutrition and
chronic inflammation, which is also associated with
hypoparathyroidism. Insulin deficiency in type 1 diabetes
might play a role in reduction of serum PTH levels. Fur-
thermore, previous studies have shown that high glucose
medium inhibits PTH secretion in cultured parathyroid
cells [22,23]. Martinez et al. also reported a similar associ-
ation between high glucose levels and hypoparathyroid-
ism; however, others could not confirm this association
[24]. Relative hypoparathyroidism is associated with ady-
namic bone disease, as well as with an increased risk of
vascular calcification and bone fracture. Vascular calcifica-
tion and bone fracture are known to dramatically increase
mortality in dialysis patients. Therefore, we suggest that
special attention should be paid to the management of
elderly diabetic patients with hypoparathyroidism.
In our survey, elderly patients were more likely to meet
treatment targets compared with younger patients on dia-
lysis. Additionally, a much lower proportion of older pa-
tients than younger patients received medications. Protein
intake, and consequently PO4 intake, are lower in older
patients, leading to an increased prevalence of malnutri-
tion. This could result in better adherence to a low PO4
diet, which is perceived as better phosphate control. A
lower body mass of elderly patients may also result in
more adequate dialysis. However, this factor might be of
less importance in the current results. Because relative
hypoparathyroidism is a more frequent finding in elderly
patients than in younger patients, we consider that the
higher prevalence of hyperparathyroidism in younger indi-
viduals could result in relatively better PTH control in the
older population.
Based on our survey results, meeting se-iPTH targets
was similar to that in the COSMOS study. [25]. A total
of 14.4% of patients had hyperparathyroidism, which is a
relatively low percentage. Despite the fact that approxi-
mately 80% of those patients did not have hypercalce-
mia, only half of those patients were taking active
vitamin D analogs. A total of 36.9% of patients had se-
iPTH levels below the target range, which is a great con-
cern because those patients have a high risk for vascular
and soft tissue calcification, as well as for bone fractures
and mortality. If iPTH levels in our patients (300±386
pg/ml) are compared with those in a Japanese dialysis
population (341±272 pg/ml) [26], we can conclude that
in Hungary, patients are under tighter control; however,
our standard deviation is higher. To decrease the pro-
portion of hypoparathyroid patients, one potential treat-
ment strategy could be the more frequent use of low
calcium dialysate solutions, which is increasingly preva-
lent in Hungary.
With regard to target levels, it should be taken into
consideration that current guidelines recommend a wider
PTH target range than the previous guidelines, but some
physicians may still manage patients according to the old
guidelines and control patients more strictly, causing a
higher prevalence of hypoparathyroidism. More than one
third of our patients were below the lower limit of the
PTH target range, which is not appropriate clinical prac-
tice. In general, among Hungarian dialysis patients, se-
iPTH levels that are too low (<120 pg/ml) are far more
frequent than (>540 pg/ml) se-iPTH levels that are too
high. The most threatened patients (n=345; 6.9%) are
those in whom se-iPTH and Ca levels are simultaneously
out of target range. We conclude that a 20% yearly mortal-
ity rate [27] among dialysis patients might partly be
caused by the high proportion of CKD-MBD patients who
are frequently out of target laboratory ranges. Only 23% of
patients with se-iPTH levels above the target range were
on calcimimetic agents. Increasing the prescription of
calcimimetics would be particularly important because of
their high potential to decrease PTH levels without hyper-
calcemic side effects. Furthermore, calcimimetics also in-
crease the sensitivity of the parathyroid gland to vitamin
D. The combination of the two drugs is particularly bene-
ficial for patients with increased serum PTH and Ca levels.
Strict local financial regulations are likely to contribute to
the low percentage of calcimimetic use. Non-Ca-based
Table 5 Numbers of treated patients and prevalence of drugs prescription based on serum iPTH (pg/ml) and Ca (mmol/l)
levels
Therapy iPTH<120 n=1849 iPTH 120–540 n=2436 iPTH>540 n=723
Ca≤2.4 n=1380 Ca>2.4 n=469 Ca≤2.4 n=2141 Ca>2.4 n=295 Ca≤2.4 n=586 Ca>2.4 n=137
Calcimimetic 13 (0.9 %) 2 (0.4 %) 64 (3.0 %) 14 (4.7 %) 133 (22.7 %) 33 (24.1 %)
Ca-PO4 binder 567 (41.1 %) 202 (43.1 %) 886 (41.4 %) 95 (32.2 %) 223 (38.1 %) 38 (27.7 %)
Non Ca-PO4 binder 155 (11.2 %) 64 (13.6 %) 383 (17.9 %) 85 (28.8 %) 207 (35.3 %) 53 (38.7 %)
Native vitamin D 28 (1.5 %) 7 (0.4 %) 93 (3.8 %) 2 (0.08 %) 32 (4.4 %) 4 (0.6 %)
Active vitamin D analogs 324 (24 %) 143 (31.6 %) 964 (45.6 %) 155 (52.94 %) 359 (62.3 %) 75 (57.1 %)
No therapy 544 (39.4 %) 152 (32.4 %) 527 (24.6 %) 60 (20.3 %) 51 (8.7 %) 15 (10.9 %)
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PO4 binders are far less frequently used than Ca-based
PO4 binders. This treatment pattern is most likely in-
fluenced by the strict rules of drug coverage.
The majority (64.6%) of patients (n=3235) were within
the normal Ca target range (2.1 -2.4 mmol/l) and there
were only 901 patients (18%) who were hypercalcemic.
With respect to international data, this result is compar-
able because in the COSMOS study [28], the percent-
ages of patients in the target range were 55% and 28%
[29] for serum Ca and PTH levels, respectively. We took
the recent KDIGO guideline into account, which allows
for a wider normal range of PTH levels. In Macedonia,
79% of patients were within the serum Ca target range.
However, in this study, the target range was wider (2.1–
2.6 mmol/l) than the target range that we used in the
current study [30].
In our survey, the percentage of patients who were
treated with native vitamin D was extremely low (3.3%).
Considering the highly prevalent vitamin D insufficiency
in the general population and also in CKD patients, all
dialysis patients should be presumed as being vitamin D
deficient. An increasing amount of evidence suggests
supplementing dialysis patients with native vitamin D
without even measuring their vitamin D status.
Our study has several limitations. A cross-sectional
survey cannot examine changes in laboratory parameters
in time because of changes in treatment strategy. There-
fore, our findings regarding treatment practice should be
evaluated carefully. Our survey was based on a single
blood sample for each patient, not allowing for possible
large intra-individual variation of laboratory parameters.
Different laboratory assays were used to measure se-
iPTH levels. However, we believe that the difference be-
tween the assays used did not greatly affect our results
and conclusions. Our survey did not capture possible
important confounding variables, such as dialysis vin-
tage, co-morbidities, residual renal function, and dialysis
adequacy, which also could have influenced the exam-
ined associations. Despite these limitations, this nation-
wide survey provides important information about our
patient population and it is able to show directions to
further improve the quality of dialysis care.
Conclusions
In summary, this was the first survey in Hungary in
which almost all patients on maintenance HD or PD
were enrolled to analyze patient characteristics and
treatment practices related to CKD-MBD. We found
significant age-related associations in ESRD patients. We
confirmed the inverse association between age and
serum iPTH levels, and this was independent of the
presence of diabetes. Oder patients were more likely to
achieve laboratory targets than younger patients. Older
patients were prescribed less medications related to
CKD-MBD than younger patients and there was a high
percentage of older subjects not receiving any relatedmedi-
cation. The majority of ESRD patients had unbalanced Ca
and PO4 metabolism. However, the target achievements of
laboratory parameters are comparable with international
data. We found a high prevalence of relative hypoparathyr-
oidism in Hungary. Last, universal administration of native
vitamin D, more frequent prescription of calcimimetics,
and non-Ca-based PO4 binders based on current guidelines
would be beneficial. Further longitudinal research needs to
be performed to determine the effect on morbidity and
mortality of age-related differences of CKD-MBD in dialysis
patients.
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